A common medication may have an unexpected effect on a serious eye condition, new research suggests.

Shares of Aldeyra Therapeutics ALDX plunged 70.7% on Tuesday after the company announced receiving a Complete Response Letter ...

After delaying its review, the FDA has rejected Aldeyra Therapeutics’ experimental dry eye disease treatment for the third time. | After delaying its review, the FDA has rejected Aldeyra Therapeutics’ ...

The FDA has, for a third time, declined to approve reproxalap for the treatment of dry eye disease, according to a press ...

With the singular exception of punctal or canalicular occlusion, when we are talking about in-office dry eye disease ...

In its complete response letter, the FDA said Aldeyra had failed to demonstrate reproxalap’s efficacy in adequate and ...

Umm, just because something can move your bowels doesn’t necessarily mean that you can move it to your eyes. Yet, some people on TikTok have been telling you to rub castor oil around and potentially ...

Patients with autoimmune thyroiditis who use semaglutide to manage their T2D have fewer TED-related diagnoses at 5 years.

Previously, the Company had received CRLs in November 2023 and April 2025 due to insufficient evidence in addressing the ...

Fluctuating vision is the most frequently cited complaint, exceeding classic discomfort symptoms, and may divert patients toward refractive explanations before DED is recognized and treated.

Dry eye has emerged as an early warning sign of autoimmune disease, appearing roughly three years before many patients receive a formal diagnosis. That gap reframes a common irritation as a potential ...